Related Experiment Video

Updated: Jun 17, 2026

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

[Antitumoral effect of proliferation signal inhibitors]

J Dumortier1

  • 1Unité de transplantation hépatique, Hôpital Edouard Herriot, pavillon H bis, Lyon, France. jerome.dumortier@chu-lyon.fr

Gastroenterologie Clinique Et Biologique
|December 17, 2009
PubMed

Insights

Mammalian target of rapamycin (mTOR) inhibitors show promise in cancer treatment by halting tumor growth and spread. These drugs also exhibit antiangiogenic effects and are being investigated for various cancers and in organ transplant patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Immunology

Background:

  • The mammalian target of rapamycin (mTOR) pathway is crucial for cell growth and is frequently dysregulated in cancer.
  • mTOR regulates tumor cell proliferation, cell cycle progression, and oncogenic signaling pathways.

Purpose of the Study:

  • To review the role of mTOR inhibitors in cancer therapy.
  • To explore the therapeutic potential of mTOR inhibitors in various cancer types and in the context of organ transplantation.

Main Methods:

  • Review of preclinical studies and clinical trial data on mTOR inhibitors (sirolimus, temsirolimus, everolimus).
  • Analysis of mTOR inhibitors' effects on cancer cell proliferation, invasion, metastasis, apoptosis, and angiogenesis.
  • Evaluation of safety profiles and efficacy in monotherapy and combination treatments.

Main Results:

  • mTOR inhibitors significantly inhibit cancer cell proliferation, invasion, metastasis, and promote apoptosis.
  • These agents possess antiangiogenic properties by suppressing vascular endothelial growth factor (VEGF) signaling.
  • Preclinical and preliminary clinical data suggest an acceptable safety profile and therapeutic potential.

Conclusions:

  • mTOR inhibitors are a promising class of drugs for cancer treatment, with demonstrated antitumoral and antiangiogenic effects.
  • Ongoing clinical trials are evaluating mTOR inhibitors across various cancer types and treatment schedules.
  • mTOR inhibitors hold potential for managing post-transplantation malignancies, particularly in liver transplant recipients.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...